Exploring the effects of luteinizing hormone-releasing hormone agonist therapy on bone health: Implications in the management of prostate cancer

Urology

Volumn 62, Issue 6 SUPPL. 1, 2003, Pages 29-35

  Chang, Sam S ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ANDROGEN; BICALUTAMIDE; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; ESTRADIOL; FLUTAMIDE; GONADORELIN AGONIST; LETROZOLE; LEUPRORELIN; PAMIDRONIC ACID; RISEDRONIC ACID; TESTOSTERONE; TILUDRONIC ACID; VITAMIN D; ZOLEDRONIC ACID;

ALCOHOL CONSUMPTION; BONE DENSITY; BONE METASTASIS; BONE MINERAL; CANCER HORMONE THERAPY; CLINICAL TRIAL; CORTICOSTEROID INDUCED OSTEOPOROSIS; DIETARY INTAKE; DRUG EFFECT; DYNAMIC EXERCISE; FRAGILITY FRACTURE; HORMONE ACTION; HUMAN; LIFESTYLE; ORCHIECTOMY; OSTEOLYSIS; OSTEOPOROSIS; PAGET BONE DISEASE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; REVIEW; SMOKING CESSATION; TREATMENT OUTCOME; VITAMIN SUPPLEMENTATION;

EID: 0346368075     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urology.2003.10.006     Document Type: Article

References (46)

1. The Medical Research Council Prostate Cancer Working Party Investigators Group: Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trial. Br J Urol 79: 235-246, 1997.
2. Messing E.M., Manola J., Sarosdy M., et al. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenopathy in men with node-positive prostate cancer. N Engl J Med. 341:1999;1781-1788.
3. Higano C.S. Side effects of androgen deprivation therapy monitoring and minimizing toxicity . Urology. 61:(suppl 2A):2003;32-38.
4. Smith M.R., Finkelstein J.S., McGovern F.J., et al. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab. 87:2002;599-603.
5. Ross R.W., Small E.J. Osteoporosis in men treated with androgen deprivation therapy for prostate cancer. J Urol. 167:2002;1952-1956.
6. Smith M.R. Osteoporosis and other adverse body composition changes during androgen deprivation therapy. Cancer Metastasis Rev. 21:2002;159-166.
7. National Institutes of Health Osteoporosis and Related Bone Diseases National Resource Center: Osteoporosis in men. Available at: http://www.osteo.org/newfile.asp?doc=r615i&doctitle=Osteoporosis+in+Men& doctype=HTML+Fact+Sheet. Accessed June 30, 2003.
8. Melton L.J., Kan S.H., Wahner H.W., et al. Lifetime fracture risk an approach to hip fracture risk assessment based on bone mineral density and age . J Clin Epidemiol. 41:1988;985-994.
9. Oden A., Dawson A., Dere W., et al. Lifetime risk of hip fractures is underestimated. Osteoporos Int. 8:1998;599-603.
10. World Health Organization: Assessment of Fracture Risk and Its Application to Screening for Postmenopausal Osteoporosis. Geneva, World Health Organization, 1994. WHO Technical Report Series, No. 843.
11. Selby P.L., Davies M., Adams J.E. Do men and women fracture bones at similar bone densities? Osteoporos Int. 11:2000;153-157.
12. Orwoll E.S. Androgens basic biology and clinical implication . Calcif Tissue Int. 69:2001;185-188.
13. Morishima A., Grumbach M.M., Simpson E.R., et al. Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J Clin Endocrinol Metab. 80:1995;3689-3698.
14. Vanderschueren D., Van Herck E., De Coster R., et al. Aromatization of androgens is important for skeletal maintenance of aged male rats. Calcif Tissue Int. 59:1996;179-183.
15. Falahati-Nini A., Riggs B.L., Atkinson E.J., et al. Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men. J Clin Invest. 106:2000;1553-1560.
16. Stepan J., Lachman M., Zverina J., et al. Castrated men exhibit bone loss effect of calcitonin treatment on biochemical indices of bone remodeling . J Clin Endocrinol Metab. 69:1989;523-527.
17. Johansen J.S., Riis B.J., Hassager C., et al. The effect of a gonadotropin-releasing hormone agonist analog (nafarelin) on bone metabolism. J Clin Endocrinol Metab. 67:1988;701-706.
18. 6-GnRH). J Clin Endocrinol Metab. 76:1993;288-290.
19. Stoch S.A., Parker R.A., Chen L., et al. Bone loss in men with prostate cancer treated with gonadotropin-releasing hormone agonists. J Clin Endocrinol Metab. 86:2001;2787-2791.
20. Basaria S., Lieb J. 2nd, Tang A.M., et al. Long-term effects of androgen deprivation therapy in prostate cancer patients. Clin Endocrinol (Oxf). 56:2002;779-786.
21. Chen Z., Maricic M., Nguyen P., et al. Low bone density and high percentage of body fat among men who were treated with androgen deprivation therapy for prostate carcinoma. Cancer. 95:2002;2136-2144.
22. Mittan D., Lee S., Miller E., et al. Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs. J Clin Endocrinol Metab. 87:2002;3656-3661.
23. Maillefert J.F., Sibilia J., Michel F., et al. Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma. J Urol. 161:1999;1219-1222.
24. Daniell H.W., Dunn S.R., Ferguson D.W., et al. Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol. 163:2000;181-186.
25. Kiratli B.J., Srinivas S., Perkash I., et al. Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer. Urology. 57:2001;127-132.
26. Diamond T., Campbell J., Bryant C., et al. The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma. Cancer. 83:1998;1561-1566.
27. Daniell H.W. Osteoporosis after orchiectomy for prostate cancer. J Urol. 157:1997;439-444.
28. Hatano T., Oishi Y., Furuta A., et al. Incidence of bone fracture in patients receiving luteinizing hormone-releasing hormone agonists for prostate cancer. BJU Int. 86:2000;449-452.
29. Townsend M.F., Sanders W.H., Northway R.O., et al. Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate carcinoma. Cancer. 79:1997;545-550.
30. Oefelein M.G., Ricchuiti V., Conrad W., et al. Skeletal fracture associated with androgen suppression induced osteoporosis the clinical incidence and risk factors for patients with prostate cancer . J Urol. 166:2001;1724-1728.
31. Oefelein M.G., Ricchiuti V., Conrad W., et al. Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol. 168:2002;1005-1007.
32. Berruti A., Tucci M., Terrone C., et al. Background to and management of treatment-related bone loss in prostate cancer. Drugs Aging. 19:2002;899-910.
33. Green J.R., Clezardin P. Mechanisms of bisphosphonate effects on osteoclasts, tumor cell growth, and metastasis. Am J Clin Oncol. 25:(suppl 1):2002;S3-S9.
34. Orwoll E., Ettinger M., Weiss S., et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med. 343:2000;604-610.
35. Smith M.R., McGovern F.J., Zietman A.L., et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med. 345:2001;948-955.
36. Diamond T.H., Winters J., Smith A., et al. The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade a double blind, randomized, placebo-controlled crossover study . Cancer. 92:2001;1444-1450.
37. Sun Y.C., Geldoff A.A., Newling D.W., et al. Progression delay of prostate tumor skeletal metastasis effects by bisphosphonates. J Urol. 148:1992;1270-1273.
38. Boissier S., Ferreras M., Peyruchaud O., et al. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res. 60:2000;2949-2954.
39. Corey E., Brown L.G., Quinn J.E., et al. Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer. Clin Cancer Res. 9:2003;295-306.
40. Saad F., Gleason D.M., Murray R., et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 94:2002;1458-1468.
41. Smith M.R. Bisphosphonates to prevent osteoporosis in men receiving androgen deprivation therapy for prostate cancer. Drugs Aging. 20:2003;175-183.
42. Abrahamsson P.A. Treatment of locally advanced prostate cancer a new role for antiandrogen monotherapy? Eur Urol. 39:(suppl 1):2001;22-28.
43. Smith M.R., Fallon M.A., Goode M.J. Cross-sectional study of bone turnover during bicalutamide monotherapy for prostate cancer. Urology. 61:2003;127-131.
44. Higano C., Stephens C., Nelson P., et al. Prospective serial measurements of bone mineral density (BMD) in prostate cancer patients without bone metastases treated with intermittent androgen suppression (IAS). Proc Am Soc Clin Oncol. 18:1999;314a. [abstract].
45. Smith M.R. Management of treatment-related osteoporosis in men with prostate cancer. Cancer Treat Rev. 29:2003;211-218.
46. Ockrim J.L., Lalani E.N., Laniado M.E., et al. Transdermal estradiol therapy for advanced prostate cancer forward to the past? J Urol. 169:2003;1735-1737.